ENLV: Enlivex Therapeutics Ltd Price to Sales

Corporate company logo of Enlivex Therapeutics, Ltd. (ENLV)

A bet on academic alliances over mergers is driving growth, and on the GURU.Markets platform, the P/S ratio dynamics visualize this trend, where the value of confirms the current level. The business foundation of Enlivex Therapeutics (ENLV) relies on the commercialization of Allocetra for sepsis therapy, while supply reliability is ensured by climate-controlled express aviation, which is critical for intensive care biologics.

ENLV Enlivex Therapeutics, Ltd. Price-to-Revenue Ratio (07/04/2022 - 11/16/2026)

Analytical breakdowns for Enlivex Therapeutics, Ltd. (ENLV)

Summary company analytics:Enlivex Therapeutics, Ltd. ENLV
Product sample of Enlivex Therapeutics Ltd

The investment attractiveness of Enlivex Therapeutics (ENLV) is based on unique patents in the field of cell therapy. The P/S ratio compares current market capitalization to annual revenue, determining the cost of one dollar of sales. By analyzing the P/S market multiple, an investor can discern the degree of asset overvaluation relative to actual income. This allows for an assessment of business resilience amid strict regulatory control and the complexities of biomanufacturing.

Competing companies

argenx - Market Cap to Revenue Ratio|P/S Multiple BNTX (biontech.de)|Abivax Corp (ABVX) - Price to Sales|ADMA Corp - P/S Multiple|Price-to-Sales Ratio PTGX|Immunovant Inc (IMVT) - Price-to-Revenue Ratio|KNSA - Price-to-Revenue Coefficient|GRFS (Grifols Biemat) - P/S Multiple|P/S Multiple Adaptive Biotechnologies Inc.|Price-to-Revenue Ratio Celldex Therapeutics (CLDX)|Price-to-Revenue Coefficient auriniapharma.com|Price-to-Revenue Ratio BioCryst Pharmaceuticals BCRX|Market Capitalization-to-Revenue Ratio VERA|Dianthus Pharma - P/S Multiple|PHVS - P/S Multiple|ABCL: P/S Multiple|TRML (Tourmaline Bio, Inc.) - Price-to-Revenue Ratio|Price-to-Revenue Ratio Intrexon|PHAR - Price-to-Revenue Multiple|P/S Multiple NKTR|Price-to-Revenue Ratio UPB (Upstream Bio Corp)|Price-to-Revenue Ratio Zenas Biopharma, Inc. ZBIO|Price-to-Revenue Coefficient immunome.com (IMNM)|Gossamer Bio Inc - P/S Multiple|Market Capitalization-to-Revenue Ratio KALV (KalVista Pharmaceuticals, Inc.)|SEPN: P/S Multiple|Market Cap to Revenue Pieris Pharmaceuticals Inc|Market Cap to Revenue SVRA|Market Cap to Revenue Rigel Pharmaceuticals (RIGL)|P/S Multiple ANAB|ATXS - Price to Sales|Price-to-Revenue Ratio enGene Corp ENGN|Price-to-Revenue Coefficient RAPT Therapeutics, Inc. (RAPT)|Aerovate - P/S Multiple|ACRS - P/S Multiple|KYTX (Kyverna Therapeutics) - Market Cap to Revenue|Price to Sales Tiziana Life Sciences Ltd. (TLSA)|Market Cap to Revenue CABA|Ventyx Biosciences (VTYX) - Price-to-Revenue Coefficient|P/S Multiple THTX|AVTX (Avalo Therapeutics, Inc) - Market Capitalization-to-Revenue Ratio|P/S Multiple ELDN (eledon.com)|AGEN - Market Cap to Revenue|CLYM - Price-to-Revenue Ratio|Price-to-Sales Ratio ZURA|ATYR: P/S Multiple|Adagene Corp (ADAG) - P/S Multiple|Market Cap to Revenue IMA|Shattuck Labs, Inc. - Price-to-Sales Ratio|Price-to-Revenue Ratio Equillium Inc (EQ)|P/S Multiple Connect Biopharma Holdings (CNTB)|Price-to-Revenue Ratio Immunic, Inc. IMUX|P/S Multiple Atara Biotherapeutics ATRA|IFRX - Price-to-Revenue Ratio|XFOR: Price-to-Revenue Ratio|ACET: P/S Multiple|CELU - Price-to-Revenue Coefficient|Price-to-Revenue Ratio inmunebio.com|Market Cap to Revenue Ratio BRNS (barinthusbio.com)|P/S Multiple KZR|P/S Multiple SAB Biotherapeutics, Inc (SABS)|P/S Multiple AKTX (Akari Therapeutics, Plc)|q32bio.com - Price-to-Revenue Ratio|GOVX: Market Cap to Revenue|edesabiotech.com (EDSA) - Market Cap to Revenue|IBIO: P/S Multiple|CARM - Price-to-Revenue Coefficient|Market Cap to Revenue XTLB|Market Cap to Revenue boltbio.com (BOLT)|Price-to-Revenue Ratio HCW Biologics Inc (HCWB)|P/S Multiple Aptevo Therapeutics, Inc. (APVO)|Price-to-Revenue Ratio aimimmuno.com AIM|Market Capitalization-to-Revenue Ratio ADTX|GRI Bio Corporation - P/S Multiple|XORTX Corp (XRTX) - Market Cap to Revenue|HIND (Vyome Holdings Inc.) - Market Cap to Revenue|revbiosciences.com (REVB) - P/S Multiple|INDP (Indaptus Corp) - P/S Multiple|Market Cap to Revenue Scinai Immunotherapeutics Ltd (SCNI)|Price-to-Revenue Ratio CalciMedica Inc (CALI)|AFMD (Affimed NV) - Market Capitalization-to-Revenue Ratio|P/S Multiple ALLK (Allakos Inc.)|P/S Multiple HOOKIPA HOOK|IGMS: Market Cap to Revenue|Market Capitalization-to-Revenue Ratio ITOS (iTeos)|OCEA: P/S Multiple|TCBP (TC BioPharm Ltd) - Price-to-Revenue Ratio|THRD (Third Harmonic Bio Inc) - P/S Multiple